Arcadia Biosciences Inc (RKDA)
Official siteCONSUMER DEFENSIVE • PACKAGED FOODS • NASDAQ
Market Cap: $1.32M
Last updated: Nov 17, 2026 at 4:39 PM ET
Arcadia Biosciences Inc (RKDA) Statistics
Arcadia Biosciences (RKDA) has a market cap of $1.32M. Its share count is up 343.63% from a year earlier. It kept -202.09% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $1.32M |
|---|---|
| Latest price (Nov 17, 2026) | $0.19 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.2x and 0.5x. Its year-end P/S ranged from 0.6x to 13.5x from 2016 to 2025.
| P/S Ratio | 0.2x |
|---|---|
| Forward P/S | 0.2x |
| P/B Ratio | 0.5x |
| P/TBV Ratio | 0.5x |
Price Statistics
The stock is down 94.97% over 52 weeks and trades 26.92% below its 50-day average.
| Beta (1Y) | 1.15 |
|---|---|
| 52-Week Change | -94.97% |
| 1-Month Change | +30.83% |
| 3-Month Change | -57.08% |
| 6-Month Change | -79.36% |
| 5-Year Change | -99.80% |
| 10-Year Change | -99.99% |
| Total Return (1Y) | -94.97% |
| Total Return (3Y CAGR) | -60.20% |
| Total Return (5Y CAGR) | -69.08% |
| Max Drawdown (1Y) | -96.22% |
| Max Drawdown (3Y) | -97.73% |
| Sharpe Ratio (1Y) | -2.89 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $0.26 |
| 200-Day Average | $0.89 |
| 52-Week Range | $0.11 to $3.87 |
| RSI (14 Days) | 45.1 |
| Average Volume (20 Days) | 1.57M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.58x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.58x |
|---|---|
| Quick Ratio | 2.82x |
| Debt / Equity | 0.00x |
| Interest Coverage | -0.09x |
Returns and Efficiency
Return on equity is -425.80% over the last 12 months, against a 5-year average of -80.93%.
| Return on Equity (ROE) | -425.80% |
|---|---|
| Return on Assets (ROA) | -216.96% |
| Return on Capital Employed (ROCE) | -54.23% |
| ROE (5Y Average) | -80.93% |
| ROA (5Y Average) | -49.90% |
| ROIC (5Y Average) | -61.64% |
| Asset Turnover | 0.76x |
| Inventory Turnover | 3.13x |
| Receivables Turnover | 8.55x |
| Cash Conversion Cycle | 13 days |
Scores
RKDA has an Altman Z-Score of -85.22, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -85.22 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $5.06M over the last 12 months is down 2.11% from the 12 months before.
| Revenue | $5.06M |
|---|---|
| Revenue Growth (YoY) | -2.11% |
| Gross Profit | $2.08M |
| Operating Income | -$3.49M |
| Pretax Income | -$7.26M |
| Net Income | -$10.23M |
| EBITDA | -$1.86M |
| EBIT | -$1.87M |
| Reported EPS (TTM) | -$3.17 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 50.85% of the $4.72M in total assets.
| Cash and Equivalents | $2.84M |
|---|---|
| Total Debt | $0 |
| Net Cash | $2.84M |
| Net Cash Per Share | $0.47 |
| Working Capital | $3.29M |
| Shareholder Equity | $2.40M |
| Book Value Per Share | $0.40 |
| Tangible Book Value | $2.36M |
| Tangible Book Per Share | $0.39 |
| Total Assets | $4.72M |
| Total Liabilities | $2.31M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$3.56M |
|---|---|
| FCF Per Share | -$1.48 |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -68.95%.
| Gross Margin | 41.14% |
|---|---|
| Operating Margin | -68.95% |
| Pretax Margin | -143.49% |
| Net Margin | -202.09% |
| EBITDA Margin | -36.68% |
| EBIT Margin | -36.88% |
| Gross Margin (5Y Average) | 23.60% |
Growth
Revenue fell 13.16% a year over 3 years.
| Revenue Growth (3Y CAGR) | -13.16% |
|---|---|
| Revenue Growth (5Y CAGR) | -9.57% |
| Book Value Per Share Growth (2Y CAGR) | -44.98% |
| Tangible Book Per Share Growth (2Y CAGR) | -45.16% |
Dividends and Yields
RKDA does not pay a dividend.
| Buyback Yield | -347.65% |
|---|---|
| Shareholder Yield | -347.65% |
Stock Splits
The last split was a 1-for-40 reverse split on Mar 1, 2023.
| Last Split Date | Mar 1, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:40 |
Peer Position
Against 5 similar companies, RKDA has the lowest P/S.
P/S RatioPeer median 1.3x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.58%
| P/S Ratio | 0.2x vs 1.3x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -2.11% vs +5.58% median |
Analyst Forecast
Consensus estimates put revenue growth at 58.50% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | +58.50% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RKDA
What is RKDA's market cap?
Arcadia Biosciences has a market cap of $1.32M.
How many shares of RKDA are outstanding?
Arcadia Biosciences has 6.07M shares outstanding. The count is up 343.63% from a year earlier.
Does RKDA pay a dividend?
No. Arcadia Biosciences does not pay a dividend.
How much debt does RKDA have?
Arcadia Biosciences has $0 of total debt and $2.84M of cash and equivalents, a net cash position of $2.84M.
RKDA pages: Overview, Charting, Earnings, Financials, Statistics, Valuation, Competitors